Disparities in the health status of different populations is linked with social, economic, and environmental disadvantages have long been known. This is reflected in a growing body of research over the past 25 years, which has revealed that disparities in the quality of care provided are also highly influenced by individual characteristics such as gender, race, ethnicity, education, income, age, geography, sexual orientation, and other factors.
The result is a 93B loss in medical costs. Learn how health equality benefit the global ecosystem and policies that work to extend cost effective health equality for all.
Orphan drugs help to fill an unmet need in the management of patients with rare diseases worldwide. The United States (US), and the European Union (EU) have adopted legislative policies to enable pathways to expedite the review, and regulatory approval of these novel treatments. These policies have enabled an increase in approvals and patient access to new treatments for people with rare disease worldwide. However not all countries have modified their regulations to account for this change. A number of emerging and frontier countries still lack effective regulatory review guidance and legislative policies to expedite the approval of orphan drug therapies and to manage costs for rare diseases.
